Predictors of adherence to concomitant antihypertensive and lipid-lowering medications in older adults: a retrospective, cohort study
- PMID: 18808213
- DOI: 10.2165/00002512-200825100-00008
Predictors of adherence to concomitant antihypertensive and lipid-lowering medications in older adults: a retrospective, cohort study
Abstract
Background: Many older individuals have concomitant hypertension and dyslipidaemia--two conditions that, together with age, increase the risk of adverse cardiovascular events. Adherence to antihypertensive (AH) and lipid-lowering (LL) therapy is therefore particularly important in older patients with concomitant hypertension and dyslipidaemia.
Objective: To determine patterns and predictors of adherence to concomitant AH and LL therapy among an older Medicare-eligible population.
Methods: Enrolees (n=4052) aged>or=65 years who initiated treatment with both AH and LL therapy within a 90-day period were studied in this retrospective cohort study conducted in a US managed care organization. Adherence to AH and LL medications was measured as the proportion of days covered by any AH and/or LL medication in each 3-month interval, from the start of concomitant therapy for up to 36 months (mean follow-up 19.5 months). In each interval, patients were considered 'adherent' to AH and LL therapy if they had filled prescriptions sufficient to cover>or=80% of days with both medication classes. A multivariable regression model evaluated potential predictors of adherence to concomitant therapy, including patient demographics, clinical characteristics and health services use patterns at baseline.
Results: The percentage of patients adherent to both AH and LL therapy declined rapidly, before stabilizing, with 40.5%, 32.7% and 32.9% adherent at 3, 6 and 12 months, respectively. At each timepoint, an additional 27.8-35.0% of patients were adherent to either AH or LL therapy, but not both. Adherence was on average greater to AH than LL therapy. After adjusting for age, sex and other potential predictors, patients were more likely to be adherent if AH/LL therapies were initiated closer together in time (adjusted odds ratio [AOR] 1.13 for 0-30 days vs 61-90 days, p=0.0563), had a history of cardiovascular disease (AOR 1.27, p=0.0004), took fewer additional medications (AOR 0.43 for six or more medications vs zero or one medication, p<0.0001) or had more outpatient physician visits in the prior year (AOR 1.26 for four to six visits vs zero to one visit, p<0.0027).
Conclusion: Adherence to concomitant AH and LL therapy among older adults is poor. Modifiable factors that may improve adherence in Medicare-eligible patients include initiating therapy concurrently and reducing patients' overall pill burden.
Similar articles
-
Predictors of adherence with antihypertensive and lipid-lowering therapy.Arch Intern Med. 2005 May 23;165(10):1147-52. doi: 10.1001/archinte.165.10.1147. Arch Intern Med. 2005. PMID: 15911728
-
[Adherence to antihypertensive and lipid-lowering medications: a problem of public health, not yet resolved].Ann Ig. 2011 Mar-Apr;23(2):173-84. Ann Ig. 2011. PMID: 21770233 Italian.
-
Does synchronizing initiation of therapy affect adherence to concomitant use of antihypertensive and lipid-lowering therapy?Am J Ther. 2009 Mar-Apr;16(2):119-26. doi: 10.1097/MJT.0b013e31816b69bc. Am J Ther. 2009. PMID: 19114872
-
Initial non-adherence to lipid-lowering medication: a systematic literature review.BMC Prim Care. 2024 Aug 5;25(1):284. doi: 10.1186/s12875-024-02524-z. BMC Prim Care. 2024. PMID: 39103774 Free PMC article.
-
A systematic review finds inconsistency in the measures used to estimate adherence and persistence to multiple cardiometabolic medications.J Clin Epidemiol. 2019 Apr;108:44-53. doi: 10.1016/j.jclinepi.2018.12.003. Epub 2018 Dec 8. J Clin Epidemiol. 2019. PMID: 30537541
Cited by
-
Obstructive Sleep Apnea and Arterial Hypertension: Implications of Treatment Adherence.Curr Hypertens Rep. 2020 Feb 3;22(2):12. doi: 10.1007/s11906-020-1015-y. Curr Hypertens Rep. 2020. PMID: 32016549 Review.
-
Antihypertensive Adherence Trajectories Among Older Adults in the First Year After Initiation of Therapy.Am J Hypertens. 2017 Oct 1;30(10):1015-1023. doi: 10.1093/ajh/hpx086. Am J Hypertens. 2017. PMID: 28535297 Free PMC article.
-
Association between adherence to calcium-channel blocker and statin medications and likelihood of cardiovascular events among US managed care enrollees.BMC Cardiovasc Disord. 2010 Jun 17;10:29. doi: 10.1186/1471-2261-10-29. BMC Cardiovasc Disord. 2010. PMID: 20565779 Free PMC article.
-
Impact of number of medications and age on adherence to antihypertensive medications: A nationwide population-based study.Medicine (Baltimore). 2019 Dec;98(49):e17825. doi: 10.1097/MD.0000000000017825. Medicine (Baltimore). 2019. PMID: 31804305 Free PMC article.
-
Improved quality of life and nonspecific symptoms with fixed-dose combination drugs.J Clin Hypertens (Greenwich). 2017 Feb;19(2):135-136. doi: 10.1111/jch.12940. Epub 2016 Oct 27. J Clin Hypertens (Greenwich). 2017. PMID: 27785875 Free PMC article. No abstract available.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical